SOUTH SAN FRANCISCO, Calif.,
June 8, 2020 /PRNewswire/ -- IDEAYA
Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused
precision medicine company committed to the discovery and
development of targeted therapeutics for patient populations
selected using molecular diagnostics, announced that it has
selected development candidate, IDE397, for its Methionine
adenosyltransferase 2a (MAT2A) Synthetic Lethality program.
The MAT2A program targets patients with tumors having
methylthioadenosine phosphorylase (MTAP) deletions. With the
nomination of IDE397 as a development candidate for the MAT2A
program, IDEAYA has initiated IND-enabling studies and is targeting
filing the Investigational New Drug (IND) application in the fourth
quarter 2020.
"With IDE397, we have achieved our preclinical target product
profile of a differentiated compound, including potency, safety
assessment, and physicochemical property characteristics.
Based on the preclinical in vivo efficacy data we have
generated, we believe IDE397 has the potential for evaluation in
both monotherapy and combination studies in select solid tumor
types with the genetic alteration of MTAP-deletion," said
Michael Dillon, Ph.D., Chief
Scientific Officer, IDEAYA Biosciences.
IDE397 Product Profile and MAT2A Program Summary:
- Monotherapy activity with robust tumor growth inhibition and
pharmacodynamic (PD) modulation in multiple endogenous MTAP-/-
in vivo models
- Monotherapy activity and tumor regression in HCT116 MTAP-/-
xenograft model
- No changes in liver enzymes or increased unconjugated bilirubin
levels observed in preclinical studies
- Favorable physicochemical properties and pharmacokinetics
observed across multiple species
- MAT2A program enabled by structure-based drug design; over 17
high resolution co-crystal structures have been resolved to enable
lead optimization
About MAT2A and MTAP-Deletion:
MTAP-null cells lack the ability to metabolize
5-methylthioadenosine, or MTA, which is an essential step in a
biochemical pathway involved in salvaging metabolite S-adenosyl
methionine, or SAM. Increased levels of MTA partially inhibit the
methyltransferase PRMT5 for which SAM is the substrate. This
partial inhibition renders MTAP-null cells more dependent on the
activity of methionine adenosyltransferase II alpha or MAT2A, an
enzyme that is responsible for the synthesis of SAM. Because of
this dependence, loss of MTAP results in synthetic lethality when
MAT2A is pharmacologically inhibited.
MTAP deletions are prevalent in approximately 15% of all human
tumors across various tumor types. Genetic profiling tests for the
deletion of MTAP or for the commonly co-deleted gene CDKN2A are
commercially available.
About IDEAYA Biosciences
IDEAYA is an
oncology-focused precision medicine company committed to the
discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's
approach integrates capabilities in identifying and validating
translational biomarkers with small molecule drug discovery to
select patient populations most likely to benefit from the targeted
therapies IDEAYA is developing. IDEAYA is applying these
capabilities across multiple classes of precision medicine,
including direct targeting of oncogenic pathways and synthetic
lethality – which represents an emerging class of precision
medicine targets.
Forward-Looking Statements
This press release
contains forward-looking statements, including, but not limited to,
statements related to (i) timing of filing of an IND for IDE397 and
(ii) the potential for evaluation in both monotherapy and
combination studies. Such forward-looking statements involve
substantial risks and uncertainties that could cause IDEAYA's
preclinical and clinical development programs, future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such risks
and uncertainties include, among others, the uncertainties inherent
in the drug development process, including IDEAYA's programs' early
stage of development, the process of designing and conducting
preclinical and clinical trials, the regulatory approval processes,
the timing of regulatory filings, the challenges associated with
manufacturing drug products, IDEAYA's ability to successfully
establish, protect and defend its intellectual property, the
effects on IDEAYA's business of the worldwide COVID-19 pandemic,
and other matters that could affect the sufficiency of existing
cash to fund operations. IDEAYA undertakes no obligation to update
or revise any forward-looking statements. For a further description
of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to the business of IDEAYA in general, see
IDEAYA's recent Quarterly Report on Form 10-Q filed on May 12, 2020 and any current and periodic reports
filed with the U.S. Securities and Exchange Commission.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ideaya-announces-nomination-of-development-candidate-ide397-for-mat2a-synthetic-lethality-program-targeting-mtap-deletion-patient-population-301071598.html
SOURCE IDEAYA Biosciences, Inc.